TG Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from TG Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $-20 of operating cash. Lower than 96% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$-20Over the last 3 years, every $100 of reported profit came with $-20 of operating cash.
Lower than 96% of Healthcare companies in United States.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$109Sales grew 22,029% in 3 years; of every extra $100 of sales, $109 became extra profit.
Higher than 82% of Healthcare companies in United States.
Asset Productivity Ratio
+22029% / +449%In 3 years sales changed by +22029% while total assets changed by +449%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-23.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 59% of Healthcare companies in United States.
Cash Cushion Ratio
−1%Debt, after subtracting cash, equals 1% of its market value (net debt).
Lower than 69% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
TG Therapeutics, Inc. owes $0.63 for every $1 it owns. Net profit rose 1812% in the year to Dec 2025.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
19.7Investors pay $19.7 for every $1 of TG Therapeutics, Inc.'s yearly profit, lower than 64% of Healthcare companies in United States.
P/B ratio
13.73The share price is 13.73 times TG Therapeutics, Inc.'s book value per share, higher than 90% of Healthcare companies in United States.
Market cap
$8.3 BThe total market value of all of TG Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 88% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$604 MWhat TG Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.95Net worth divided by the number of shares. The share price of $54.17 is 13.7 times this, which is the P/B above.
Return on equity (ROE)
100.3%TG Therapeutics, Inc. earned 100.3% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
Owes vs Owns
0.63×TG Therapeutics, Inc. owes $0.63 for every $1 it owns (moderate), higher than 67% of Healthcare companies in United States.
Dividend yield
NoneTG Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+87%Revenue rose 87% in the year to Dec 2025, and grew 505% a year on average over 3 years.
Profit growth
+1812%Net profit rose 1812% in the year to Dec 2025.
Profit margin
72.6%TG Therapeutics, Inc. keeps $73 of every $100 of revenue as net profit.
Cash quality
-0.1×Cash from TG Therapeutics, Inc.'s business was -0.1× its reported profit in the year to Dec 2025 — the business used cash even though it reported a profit.
Interest cover
4.6×TG Therapeutics, Inc.'s operating profit covered its interest costs 4.6 times in the year to Dec 2025.
Cash vs debt
Net debtTG Therapeutics, Inc. had $112 M more debt than cash (net debt) at Dec 2025.
Questions
What is TG Therapeutics, Inc.'s P/E ratio?
Investors pay $19.7 for every $1 of TG Therapeutics, Inc.'s yearly profit, lower than 64% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For TG Therapeutics, Inc.: $8.3 B ÷ $604 M (30 Jun 2026) = 13.7.
What is TG Therapeutics, Inc.'s return on equity?
TG Therapeutics, Inc. earned 100.3% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
How much does TG Therapeutics, Inc. owe compared with what it owns?
TG Therapeutics, Inc. owes $0.63 for every $1 it owns (moderate), higher than 67% of Healthcare companies in United States.
Does TG Therapeutics, Inc. pay a dividend?
No. TG Therapeutics, Inc. does not currently pay a dividend.
Is TG Therapeutics, Inc.'s revenue growing?
Revenue rose 87% in the year to Dec 2025, and grew 505% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.